Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — FY2018 Earnings Presentation

24 slides from Paratek Pharmaceuticals's earnings presentation, Feb 27, 2019

  1. Slide 1: Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update

    Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update February 27, 2019 Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. Exhibit 99.2

  2. Slide 2: Q4 & FY 2018 Earnings Call Agenda

    Q4 & FY 2018 Earnings Call Agenda Introduction Ben Strain, Executive Director, Investor Relations & Corporate Communications Fourth Quarter Overview and Business Update Michael F. Bigham, Chief Executive Officer and Chairman of the Board Commercial Update Adam Woodrow, Chief Commercial Officer Finan

  3. Slide 3: Forward-looking statements

    Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The info

  4. Slide 4: Fourth Quarter & FY 2018 Overview & Business Update

    Fourth Quarter & FY 2018 Overview & Business Update Michael F. Bigham, Chief Executive Officer & Chairman of the Board Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

  5. Slide 5: NUZYRA Approved, Launched & Available in the U.S.

    NUZYRATM Approved, Launched & Available in the U.S. First FDA approved, once-daily oral and IV antibiotic to treat both CABP and ABSSSI in nearly 20 years Launched in U.S. February 2019

  6. Slide 6: The New England Journal of Medicine Published OPTIC and OASIS-1 Results

    The New England Journal of Medicine Published results from the OPTIC and OASIS-1 Phase 3 clinical trials of NUZYRA Publication affirmation of the potential positive clinical impact NUZYRA can play in supporting the battle against the growing health challenge of antibiotic resistance Once-daily oral

  7. Slide 7: NUZYRA IP Protection and Market Exclusivity

    NUZYRA IP Protection and Market Exclusivity GAIN Act Ensures 10 Yrs.’ Market Exclusivity and Patent Term Extension protection to at least 2030 Patent Term Extension (PTE) Key Composition of Matter Patent (U.S. 7,553,828) Expires June 2023 2000 2005 2010 2015 2020 2025 2030 ‘828 Patent Issued Approva

  8. Slide 8: Paratek Pipeline

    Paratek Pipeline Compelling Life-cycle Opportunities Research Preclinical Phase 1 Phase 2 Phase 3 Registration Marketed+ Commercial Rights SEYSARATM (sarecycline) (U.S.) (ex-U.S.) (Global*) uUTI (Oral only) – QIDP ABSSSI (IV & Oral) – QIDP + SPA CABP (IV & Oral) – QIDP + SPA Inflammatory Acne (Acne

  9. Slide 9: Strengthening the Balance Sheet

    Strengthening the Balance Sheet Summary of Deal terms: Non-recourse, SEYSARA royalty-backed loan with HealthCare Royalty Partners Principal amount of $32.5 million, to be funded May 1, 2019 Interest rate 12% per annum paid quarterly Royalty payments in excess of accrued interest on the loan will be

  10. Slide 10: Strong Track Record Delivering on Milestones

    Strong Track Record Delivering on Milestones Omadacycline Events Timing Results ABSSSI Phase 3 data: IV & oral Q2 2016 Positive Phase 3 data UTI Phase 1b data: PK/PD Q4 2016 Proof-of-principle CABP Phase 3 data: IV & oral Q2 2017 Positive Phase 3 data ABSSSI Phase 3 data: Oral-only Q3 2017 Positive

  11. Slide 11: Commercial Update

    Commercial Update Adam Woodrow, Chief Commercial Officer Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

  12. Slide 12: There are Unmet Needs that NUZYRA Will Address

    More Oral Options New Therapies to Overcome Drug Resistance Greater Safety Alternative to Quinolones There are Unmet Needs that NUZYRA Will Address Reduce Hospital Length of Stay Reduce Nursing Time Lack of Different Class Options Reduce Usage of Multi-Drug Combinations NUZYRA Attributes Provide A M

  13. Slide 13: Ensure Seamless Transition from Hospital to Home

    Ensure Seamless Transition from Hospital to Home Continuity of Care Providing Access to Oral NUZYRA Continuity of Care Prevent gap in care Sample / Bridge Program (as needed) Reimbursement Support Services Affordability Program 3 Distribution Network IV Formulation National & Regional Distributors O

  14. Slide 14: Success Begins in the Hospital with Specialists

    Success Begins in the Hospital with Specialists “Go-Home” Strategy to Minimize Hospital Stay IDs ER HCPs Hospitalists Pulmonologists PharmD IDs Allied HCPs Launch and Beyond HOSPITAL Internal Medicine Primary Care Provider NPs, PAs Urgent Care Year 2 and Beyond COMMUNITY

  15. Slide 15: Focused Launch Targeting Early Adopters

    Focused Launch Targeting Early Adopters Expansion to ~80 Representatives by Year End 2019 Physician Segments Guideline and protocol driven Wait for Early Adopters to trial and use Convenient features with IV to oral transition Focused on broad spectrum and efficacy Launch in February 2019 with 40 Sa

  16. Slide 16: Additional Tools to Support NUZYRA Adoption

    Additional Tools to Support NUZYRA Adoption

  17. Slide 17: Field Force Has Two Simultaneous Objectives

    Influencers: IDs PharmD IDs Pharmacy Directors Microbiologists = Field Force Has Two Simultaneous Objectives Institutional Access + Demand Generation Adoption Formulary/Protocols Specialty Access & Buying + Institutional Access Prescribers: IDs ER Hospitalists Pulmonologists Trial & Usage Demand Gen

  18. Slide 18: Early Indicators to Track Performance

    Early Indicators to Track Performance 1 Covered Lives Institutional Access 3 months Post-Launch 33% of covered lives under contract 12 months Post-Launch 66% of covered lives under contract 12 months Post-Launch 70% of 800 targeted institutions

  19. Slide 19: Financial Update

    Financial Update Douglas W. Pagán, Chief Financial Officer Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

  20. Slide 20: Condensed Consolidated Statements of Operations

    Condensed Consolidated Statements of Operations (unaudited) (in thousands, except loss per share data) Three Months Ended December 31, Year Ended December 31, 2018 2017 2018 2017 Revenue Collaboration and royalty revenue $ 17,017 $ 5,072 $ 17,117 $ 12,616 Total revenue 17,017 5,072 17,117 12,616 Ope

  21. Slide 21: Strong Balance Sheet

    Strong Balance Sheet Key Metrics (unaudited) 12/31/18 balance Total Cash, Cash Equivalents, and Marketable Securities $292.8 million Long-term Debt Obligation $229.0 million Basic Shares Outstanding 32,284,602 Total Potentially Dilutive Securities* 16,709,048 * Includes common stock issuable under t

  22. Slide 22: 2019 U.S. NUZYRA Net Product Revenue Guidance

    2019 U.S. NUZYRA Net Product Revenue Guidance Today: Slower starts…But with the Right Attributes, a Strong Finish Recent AB Launches: antibiotics launched since 2010 that have at least 36 months of data - Avycaz, Dalvance, Orbactiv, Sivextro, Teflaro, & Zerbaxa (does not include Dificid or new formu

  23. Slide 23: Closing Remarks

    Closing Remarks Michael F. Bigham, Chief Executive Officer & Chairman of the Board Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

  24. Slide 24: Well-Positioned for Future Growth

    Well-Positioned for Future Growth Focused on Execution + New Value Creation Near-term Focus New Value Creation Launch of NUZYRA Prudent Operating Expense Management Non-Dilutive Sources of Capital Life-cycle Opportunities for NUZYRA Bio-Defense Product / Pipeline Expansion

Paratek Pharmaceuticals — FY2018 Earnings Presentation on 6ix